Thumbnail Image
Publication

Drug Pricing Investigation: Novartis--Gleevec

House Committee on Oversight and Reform
Abstract
The House Committee on Oversight and Reform investigated Novartis International AG's actions regarding Gleevec, a drug used for treating chronic myeloid leukemia. The report, based on over 100,000 pages of internal documents, scrutinizes Novartis' pricing strategies, business practices, and efforts to minimize generic competition. The report underscores the broader issue of pharmaceutical price increases and the need for systemic reforms such as Medicare negotiation.
Date
2020-10-01
Document Type
House Staff Report
Serial Number
Document Length
46 pages
Congress
116
Show all metadata
Files
Thumbnail Image
2020-10-01_R-Drug_Pricing_Investigation-(Novartis-Gleevec)-116C.pdf
Adobe PDF, 2.03 MB
Thumbnail Image
2020-10-01_R-Novartis-Gleevec-(selected_docs)-116C.pdf
Adobe PDF, 4.03 MB
URI
https://hdl.handle.net/20.500.14300/1172
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Related Hearings
Press Releases and Contextual Information
Collections
House Oversight Committee